QUOTE AND NEWS
Motley Fool  May 20  Comment 
Shares of the clinical-stage biotech Sarepta Therapeutics bolted higher by over 50% today. Here's why.
Motley Fool  May 10  Comment 
BioMarin Therapeutic Inc. and Amicus Therapeutics, Inc. are working on ultra-rare disease drugs that could attract an acquirer.
Benzinga  May 6  Comment 
In a report published Wednesday, Baird analysts upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT). The price target was raised from $16 to $20. The upgrade follows the NDA submission by the company's competitor BioMarin Pharmaceutical, Inc....
Motley Fool  May 1  Comment 
Vimizim steals the show as investors wait for an FDA decision on drisapersen
Benzinga  May 1  Comment 
In a report published Friday, Cowen and Company analysts maintained an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), with a price target of $125. BioMarin reported its Q1 revenue at $203.3MM, in-line with consensus. Its...
newratings.com  Apr 30  Comment 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) reported a first-quarter net loss of $67.5 million or $0.43 per share, compared to a loss of $38.1 million or $0.27 per share, prior year. Adjusted loss per share was $0.16, for the...
Motley Fool  Apr 30  Comment 
Focus will be on the potential approval of drisapersen, but don't forget about BioMarin's other drugs.
TheStreet.com  Apr 28  Comment 
SAN RAFAEL, Calif. (TheStreet) -- If all goes well (insert asterisk here), BioMarin Pharmaceutical will secure approval before the end of the year for the first drug to treat the underlying genetic cause of Duchenne muscular dystrophy DMD, a...
TheStreet.com  Apr 28  Comment 
NEW YORK (TheStreet) -- Shares of BioMarin Pharmaceutical  rose 0.88% to $118 in pre-market trading Tuesday after CEO Jean-Jacques Bienaime appeared on Jim Cramer's Mad Money on CNBC on Monday night. Bienaime said the company submitted...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki